Waters Corporation (wat)
WAT — Company Overview
Investors tracking WAT follow a Diagnostics & Research name listed on NYQ within Healthcare.
| Ticker | WAT |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Exchange | NYQ |
| Market cap | $41.29B |
| Last price | $420.57 |
| Size category | Large Cap |
WAT — Business Description
The business profile of Waters Corporation (WAT) reflects its role in Diagnostics & Research. Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and d…
Official website: https://www.waters.com.
WAT — Investment Thesis
Waters Corporation (WAT) attracts investors weighing Diagnostics & Research fundamentals against current market pricing.
- Revenue is expanding at roughly 113.4% year-over-year (public data).
- Trailing P/E of 107.56× implies elevated growth expectations at the current price.
- Forward P/E (25.42×) is below trailing P/E — earnings may be expected to improve.
- Equity market capitalization is approximately $41.29B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
WAT — Financial Health
WAT financial profile reflects operating efficiency and capital structure using available market fundamentals.
Profit margin near 3.6% leaves a narrower cushion versus higher-margin peers. Negative free cash flow of $-142.07M may require careful capital allocation.
| Trailing P/E | 107.56× |
| Forward P/E | 25.42× |
| Price / Sales | 8.89× |
| Price / Book | 2.72× |
| Gross margin | 56.3% |
| Operating margin | 9.4% |
| Profit margin | 3.6% |
| Return on equity | 1.9% |
| Debt / Equity | 36.05 |
| Free cash flow | $-142.07M |
WAT — Growth Outlook
Growth outlook for Waters Corporation (WAT) depends on demand trends in Diagnostics & Research and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 113.4% indicates strong top-line momentum.
- Price is 2.9% below the 52-week high.
WAT — Competitive Position
Waters Corporation (WAT) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Diagnostics & Research.
- Market capitalization of $41.29B places WAT among large-cap peers.
- Gross margin near 56.3% may reflect pricing power or favorable mix.
WAT — Strengths
Strengths for Waters Corporation (WAT) inferred from public financial metrics:
- Revenue growth of 113.4% year-over-year.
- Gross margin of 56.3% supports competitive unit economics.
- Moderate leverage (debt/equity 36.05).
- Large Cap scale ($41.29B) may provide distribution and funding advantages.
- Price near 52-week highs — positive price momentum on public markets.
WAT — Weaknesses
Weaknesses and pressure points for Waters Corporation (WAT) based on available data:
- Elevated trailing P/E (107.56×) limits valuation margin of safety.
- Thin profit margin (3.6%).
- Negative free cash flow ($-142.07M).
WAT — Opportunities
- Sustained revenue growth (113.4%) could support multiple expansion if margins hold.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
WAT — Risks
- Rich valuation (P/E 107.56×) increases downside if growth slows.
- Thin margins leave less room for operational missteps.
WAT — Summary
Waters Corporation (WAT) is a large-cap Healthcare company focused on Diagnostics & Research, listed on NYQ. Last price $420.57 with market cap $41.29B. Trailing P/E 107.56×. Revenue grew 113.4% year-over-year per public data. Notable strengths include revenue growth of 113.4% year-over-year. Key watch items include elevated trailing p/e (107.56×) limits valuation margin of safety. Review free estimates and earnings pages for WAT; upgrade for institutional ownership and live headlines.
Start Free — open WAT in Vest Terminal
Access live data, filings, ownership, and analysis for Waters Corporation.
Waters Corporation FAQ
What does Waters Corporation (WAT) do?
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology syste…
What is WAT's P/E ratio?
Waters Corporation has a trailing P/E of 107.56× based on publicly available market data.
Does WAT pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is WAT in?
Waters Corporation is classified in Healthcare (Diagnostics & Research) on NYQ.
What is WAT's market capitalization?
Approximate market cap: $41.29B.
What are the main risks for WAT?
Key risks include elevated valuation, among factors on this page.
What are the strengths of WAT?
Potential positives include revenue growth of 113.4% year-over-year, gross margin of 56.3% supports competitive unit economics.
Where can I get analyst estimates for WAT?
Public analyst price targets and consensus for Waters Corporation are on the free /stocks/wat/estimates page. Deeper estimate history and models are available in Vest Terminal.